Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark Remedies

The American Society Of Hematology Announces New Honorific Award
The American Society of Hematology (ASH) announces the debut of the Ernest Beutler Lecture and Prize, to be awarded at ASH"s annual meeting in December. The inaugural recipients are Thomas Maniatis, PhD, of Harvard University, and Yuet Wai Kan, MD, of the University of California - San Francisco.
generic viagra online
Studies Examine Morning Sickness Drug, Progesterone Use To Prevent Premature Birth
The following summarizes news coverage on two pregnancy-related studies. ~ Morning sickness: The commonly prescribed heartburn drug metoclopramide -- sold generically and under the brand-names Reglan, Octamide and Maxolon -- can be used to treat morning sickness without harming the health of the fetus, according to a study published on Thursday in the New England Journal of Medicine, Time reports. The drug, which also has anti-nausea properties, is not FDA-approved for use in pregnant women in the U.S., though it is commonly prescribed in European and other countries to treat morning sickness (Park, Time, 6/10). According to the Los Angeles Times, U.S. physicians occasionally prescribe metoclopramide to treat severe morning sickness cases. The new study found that there were no statistically significant differences between infants born to women who took metoclopramide and those who did not. Researchers said that the findings "provide reassurance regarding the safety of metoclopramide for the fetus when the drug is given to women to relieve nausea and vomiting during pregnancy." The study involved 81,703 births among women enrolled in Israel"s largest health HMO, including 33,458 who used the drug (Maugh, Los Angeles Times, 6/11). Jennifer Niebyl, a professor of obstetrics and gynecology at the University of Iowa, said, "There are very few drugs approved for use in the first trimester of pregnancy. But this study could lead to metoclopramide getting approved to treat morning sickness because this is good data with big numbers" (Time, 6/10).~ Progesterone: The hormone progesterone was not effective at preventing premature births among women pregnant with twins, despite evidence suggesting its effectiveness at preventing premature births in single pregnancies, according to a University of Edinburgh study published in the journal Lancet, Reuters reports. Multiple pregnancies have a larger health risk for women and significantly increase the likelihood of miscarriage, premature birth and long-term health problems. The study involved 500 women who took either progesterone or a placebo daily for 10 weeks. Although previous studies have shown that progesterone might prevent premature birth in certain high-risk pregnancies, the new findings show the treatment did not reduce the likelihood of premature delivery or a fetus dying in utero in twin pregnancies. Twenty-five percent of women delivered or had a fetus die before 34 weeks in the progesterone group, compared with 20% in the placebo group (Kahn, Reuters, 6/10).
News of the day
Blogs Comment On Sotomayor Confirmation Hearings, Health Reform, Other Topics
The following summarizes selected women"s health-related blog entries.~ "Judge Sotomayor Provides Important Testimony on the Constitutional Right to Privacy and Its Application to Reproductive Rights," Marcia Greenberger, Womenstake: "One major line of questions, asked repeatedly throughout the hearings" for President Obama"s Supreme Court nominee Sonia Sotomayor was her "views on the constitutional right to privacy," Greenberger writes, adding, "Given that this right is central to women"s lives, protecting" such "decisions involving whether to bear children ... and having consensual adult sexual relations, it is important to analyze Judge Sotomayor"s answers carefully." According to Greenberger, because Sotomayor "had not ruled directly on the right to privacy as a federal judge, her testimony in this area warrants particular attention." Following questions from senators such as Herb Kohl (D-Wis.), Orrin Hatch (R-Utah) and Dianne Feinstein (D-Calif.), Sotomayor portrayed a "clear agreement with the right to privacy and strong description of the court"s current precedents regarding Roe and women"s health," which "lend[s] further support to the view from her legal record that she would not undermine Roe v. Wade if confirmed to the Supreme Court" (Greenberger, Womenstake, 7/16). ~ "Major Steps Forward for Health Care Reform," Thao Nguyen, Womenstake: Nguyen, outreach manager for the National Women"s Law Center, reports that the health care reform legislation passed by the Senate Health, Education, Labor and Pensions Committee is "particularly important for women because of the critical headway it makes towards women"s ability to secure access to quality, affordable health care throughout their lives." The bill "works towards confronting many of the particular obstacles faced by women in our current health care system," such as banning the "discriminatory" practice of basing insurance premiums on gender, even when maternity benefits are excluded, Nguyen writes. The bill also bans insurance companies from rejecting patients based on medical history, which has prevented many domestic violence survivors and women who have had caesarean sections from obtaining coverage. Nguyen concludes that "the momentum for health care reform could not have come at a more needed time" because women and their families "need quality, affordable and comprehensive health more than ever" (Nguyen, Womenstake, 7/15).~ "Democrats for Life of America Ousts Member Who Supports Contraception," Feministing: Feministing reports that Democrats for Life of America removed Rep. Tim Ryan (D-Ohio) from its advisory board because he supports efforts to improve access to contraception. According to Ryan, he was dismissed from the board after four years after attempting to persuade the group to support contraceptive use as a way to avoid unintended pregnancies. According to the blog, "This is why we call anti-choicers "anti-choice": because they"re not just about making abortion illegal." It adds, "They don"t want women to have access to contraception either -- something that 98% of American women will use at some point in their lives" (Feministing, 7/15). ~ "Umpires, Perspective and the Supreme Court," Jim Wallis, Sojourners" "God"s Politics": "During his opening remarks for his own confirmation hearing in 2005, Chief Justice [John] Roberts made" an analogy between judges and umpires "that has gotten a lot of play in the media and has already been used quite a few times during" Sotomayor"s confirmation hearing, Wallis writes. He adds that "nothing in the world would frustrate me more than an umpire who would call the game differently based upon the color of the jersey that" players were wearing. "But I haven"t seen that happen," Wallis writes, adding, "In fact, the biggest problem we face isn"t an umpire that has favored one team over the other, but umpires who make mistakes in their rulings and judgment because of their lack of perspective." He adds that Sen. Jeff Sessions (R-Ala.) and "others w
Endocrinology

Sirona Biochem Optimizes Key Test For Diabetes And Obesity Drug Development

Sirona Biochem Corp. (TSX-V: SBM) announced it is now ready to begin testing its novel new compounds to fight diabetes and obesity. The completion of the company"s key SGLT biological assessment test and testing will be done under contract with Richmond, BC based SignalChem. Sirona Biochem owns the worldwide rights to a library of potential new sodium glucose transporter (SGLT) inhibitors developed to treat diabetes and obesity. SGLT Inhibitors are a novel new drug class currently under development that block the reuptake of excess sugars from urine in the kidney which can then reduce high blood sugar to normal levels. Excess sugar in the blood is a primary medical challenge associated with treating diabetes and obesity. Sirona has a research and development agreement with TFChem (Rouen, France), where a significant number of SGLT drug analogs are being prepared for first stage evaluation. Preliminary primary stage testing conducted earlier this year provided positive indications to support Sirona Biochem"s project and provided key insights to optimize the new test that is now ready for use to evaluate the next library set of molecules. Mark Senner, President, explained, "SGLT inhibitors are a new and exciting class of compounds that have great promise to treat both diabetes and obesity which are now at epidemic levels worldwide. This new drug class is one considered to have extraordinary market potential in the fight against diabetes and obesity. "Development of this new drug class however is challenging due to the fragile nature of these "sugar" based molecules that render them unstable and difficult to develop for clinical use. Given this challenge, it is believed that the use of the patented GlycoMim® technology, licensed from TFChem to develop SGLT Inhibitors, will increase drug stability and, therefore, improve their overall clinical effectiveness. Potential licensing and development partners have expressed interest in our concept of improving molecules in this new drug class. We intend to develop "best in class" SGLT Inhibitors through use of this technology. "The key and critical first test has been developed and optimized for use by SignalChem under contract from Sirona Biochem. Through use of this proprietary test, the company will be able to determine which molecules have the desired potency and selectivity compared to a reference standard. Screening of the current library of compounds will generate key data for ongoing drug development and provide first stage proof of concept necessary to secure future partnering opportunities. Sirona"s scientific team aims to identify lead compounds by the end of 2009," continued Senner. "The results from our new optimized test will be critical to direct our ongoing development of novel new SGLT inhibitors. The development and optimization of this sophisticated test, completed by SignalChem, is a significant and key milestone achievement for us. We are very pleased with the progress that we are making on our SGLT drug development program," commented Senner. Upon selection of compounds with the desired potency and selectivity for the SGLT 2 carrier protein, further preclinical screening for cytotoxicity, ADME properties, pharmacokinetics and in vivo efficacy will need to be carried out to select compounds for future clinical development. The primary objective of this critical first stage development plan with SignalChem was to develop, qualify and optimize the key test required for the initial development of SGLT inhibitors. Investors are invited to visit the Sirona Biochem website at: http://www.sironabiochem.com where we feature the most recent information about the company and its activities. Alternatively, investors are able to e-mail all questions and correspondence to info@sironabiochem.com where they can also request to be added to the investor e-mail list to receive all future press releases and updates or call John Dougherty, Corporate Development at 604-641-4466. Sirona Biochem Corp.


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009